Prolactin response to nemonapride, a new antipsychotic drug, in schizophrenic patients

Otani, Koichi; Kondo, Tsuyoshi; Yasui, Norio; Suzuki, Akihito; Furukori, Hanako; Kaneko, Sunao; Ohkubo, Tadashi; Nagasaki, T.; Sugawara, Kazunobu; Hayashi, Kyozo

doi:10.1002/(sici)1099-1077(199711/12)12:6<591::aid-hup926>3.0.co;2-u

Cited by 18 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of previous studies on the response of prolactin to antipsychotics used C 0 (Harnryd et al, 1984;Linkowski et al, 1984;Meltzer et al, 1983;Otani et al, 1993Otani et al, , 1997Sawamura et al, 2006;Yasui et al, 1998;Yasui-Furukori et al, 2001, 2008. Similar to the results published in these studies, prolactin C 0 during risperidone treatment was significantly higher than during treatments with olanzapine or perospirone.…”

Section: Discussionsupporting

confidence: 79%

Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients

Yasui‐Furukori

Furukori

Sugawara

et al. 2010

Human Psychopharmacology

View full text Add to dashboard Cite

Hyperprolactinemia is a frequent consequence of treatment with some antipsychotic agents. Although prolactin secretion varies over the course of a day and during psychological circumstances, there is little information in the literature regarding the time dependence of the prolactin response to antipsychotics. We evaluated prolactin levels in schizophrenic patients receiving risperidone (3 mg twice daily), olanzapine (10 mg twice daily), or perospirone (16 mg twice daily) for at least 4 weeks. The subjects were compared to matched healthy controls. Plasma sample collection for quantification of drug and prolactin levels was conducted before and 2, 4, 6, 8, and 12 h after the morning dosing. Prolactin concentrations before dosing during risperidone treatment were significantly higher than during treatment with olanzapine and perospirone in females. The daily fluctuation of prolactin concentration after perospirone treatment was larger than that observed after risperidone and olanzapine treatments. Areas under the plasma concentration-time curves was greatest in subjects treated with risperidone, followed by perospirone and finally by olanzapine. These findings suggest that daily fluctuations in prolactin concentration after perospirone treatment are larger than following treatment with risperidone and olanzapine. The plasma concentration of prolactin during perospirone treatment therefore depends on the time of sampling.

show abstract

Section: Discussionsupporting

confidence: 79%

Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients

Yasui‐Furukori

Furukori

Sugawara

et al. 2010

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Both drugs have potent antagonistic effects for dopamine D 2 ‐like receptors in contrast to very weak affinity for other receptors such as dopamine D 1 , 5‐HT 2 , norepinephrine, and acetylcholine 18,19 . The authors previous studies 20,21 showed that these drugs considerably increased prolactin concentrations in patients with schizophrenia, providing in vivo evidence for the strong DRD 2 blockade property. Therefore, these two drugs have similar pharmacological properties despite their chemical structural differences.…”

Section: Introductionmentioning

confidence: 96%

Dopamine D₂ receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia

Sakumoto

Kondo

Mihara

et al. 2007

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Previous reports have shown that both A1 allele carriers of TaqI A and Del allele non-carriers of -141C Ins/Del for dopamine D2 receptor (DRD2) gene polymorphisms have a better antipsychotic drug response. The present study aimed to examine the validity of a combination of these two DRD2 polymorphisms as predictors for response to DRD2 antagonists. The subjects consisted of 49 acutely exacerbated inpatients with schizophrenia treated with bromperidol (30 cases, 6-18 mg/ day) or nemonapride (19 cases, 18 mg/day) for 3 weeks. Brief Psychiatric Rating Scale and Udvalg for Kliniske Undersøgelser side-effects rating scale were used for clinical assessments. DRD2 genotypes were determined using a polymerase chain reaction method. In the overall 49 subjects, combined DRD2 polymorphisms weakly predicted the response to DRD2 antagonists (Fisher exact test, P = 0.049), that is, good response in A1(+) or Del(-) subjects and poor response in A1(-) plus Del(+) subjects. In the former subjects, non-responders with A1(+) or Del(-) showed higher scores of psychic, extrapyramidal and total side-effects. At therapeutic doses (6-8 mg/day haloperidol equivalent dose) in 30 subjects, the predictability of response was greatly increased (Fisher exact test, P < 0.0045) with higher positive and negative predictive values (78.3% and 85.7%, respectively). These findings suggest that combined DRD2 polymorphisms can be used as a pretreatment marker for response to DRD2 antagonists at therapeutic doses, and that A1(+) or Del(-) subjects are highly sensitive to DRD2 antagonists, expressed as either treatment responders or nonresponders vulnerable to extrapyramidal symptoms.

show abstract

No relationship betweenTaq1 a polymorphism of dopamine D2 receptor gene and extrapyramidal adverse effects of selective dopamine D2 antagonists, bromperidol, and nemonapride in schizophrenia: A preliminary study

et al. 2000

View full text Add to dashboard Cite

The relationship between Taq1 A polymorphism of dopamine D(2) receptor (DRD(2)) gene and extrapyramidal adverse effects of bromperidol and nemonapride, which are both antipsychotic drugs with selective and potent DRD(2) antagonistic property, was investigated in Japanese schizophrenic inpatients. Twenty-seven patients were treated with bromperidol at 6 or 12 or 18 mg/day, while 25 patients were treated with nemonapride at 18 mg/day. The duration of treatment was 3 weeks. The A1 and A2 alleles were determined by PCR. The extrapyramidal adverse effects were assessed by the Udvalg for Kliniske Unders¿ogelser side effects rating scale. Six patients were homozygous for the A1 allele, 27 were heterozygous for the A1 and A2 alleles, and 19 were homozygous for the A2 allele. There were no significant differences in the incidences or severity of extrapyramidal adverse effects between the patients with one or two A1 alleles and those with no A1 allele. The present study suggests that Taq1 A polymorphism is not related to the development of extrapyramidal adverse effects during acute phase of bromperidol and nemonapride treatments.

show abstract

Prolactin response to nemonapride, a new antipsychotic drug, in schizophrenic patients

Cited by 18 publications

References 12 publications

Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients

Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients

Dopamine D₂ receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia

No relationship betweenTaq1 a polymorphism of dopamine D2 receptor gene and extrapyramidal adverse effects of selective dopamine D2 antagonists, bromperidol, and nemonapride in schizophrenia: A preliminary study

Contact Info

Product

Resources

About

Prolactin response to nemonapride, a new antipsychotic drug, in schizophrenic patients

Cited by 18 publications

References 12 publications

Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients

Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients

Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia

No relationship betweenTaq1 a polymorphism of dopamine D2 receptor gene and extrapyramidal adverse effects of selective dopamine D2 antagonists, bromperidol, and nemonapride in schizophrenia: A preliminary study

Contact Info

Product

Resources

About

Dopamine D₂ receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia